Sensus Healthcare, Inc. Q3 2025 Earnings Recap

SRTS Q3 2025 November 7, 2025

Get alerts when SRTS reports next quarter

Sensus Healthcare's Q3 2025 performance showcases significant advancements, including the introduction of new CPT codes for superficial radiotherapy, which are expected to drive increased demand and enhanced reimbursement.

Earnings Per Share Beat

$-0.06 vs $-0.11 est.

+45.5% surprise

Revenue Beat

6884000 vs 6312750 est.

+9.0% surprise

Market Reaction

1-Day +19.32%

5-Day +30.68%

30-Day +15.34%

See SRTS alongside your other holdings

Add to your portfolio — free

Key Takeaways

CMS has established new dedicated CPT codes for superficial radiotherapy, promising over 300% reimbursement increases per treatment fraction.
The company recorded a 20% growth in FDA treatment volumes from Q2, marking the third consecutive quarter of double-digit growth; total treatments rose 157% since the program's launch.
Sensus shipped 16 SRT systems in Q3, reaching over 900 systems sold globally, with an expectation to hit 1,000 by 2026.
Strong cash position increased to $24.5 million, aided by improved working capital management, positioning the company to meet anticipated demand.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit SRTS on AllInvestView.

Next Q1 2026